TY - JOUR
T1 - Human C/EBP-ε activator and repressor isoforms differentially reprogram myeloid lineage commitment and differentiation
AU - Bedi, Richa
AU - Du, Jian
AU - Sharma, Arun K.
AU - Gomes, Ignatius
AU - Ackerman, Steven J.
PY - 2009/1/8
Y1 - 2009/1/8
N2 - CCAAT enhancer-binding protein-epsilon (C/EBP-ε) is required for the terminal differentiation of neutrophils and eosinophils. Human C/EBP-ε is expressed as 4 isoforms (32,30,27, and 14 kDa) through differential RNA splicing, and alternative promoters and translational start sites. The C/EBP-ε32/30 isoforms are transcriptional activators, whereas C/EBP-ε27 interacts with and represses GATA-1 transactivation of eosinophil promoters. C/EBP-ε14 contains only DNA-binding and -dimerization domains and may function as a dominant-negative regulator. To define functional activities for these C/EBP-ε isoforms in myelopoiesis, human CD34+ progenitors were transduced with internal ribosomal entry site-enhanced green fluorescent protein retroviral vectors encoding the 32/30, 27, and 14-kDa isoforms, purified by fluorescence-activated cell sorter, and analyzed in colony-forming assays and suspension cultures. Progenitors transduced with C/EBP-ε32/30 default exclusively to eosinophil differentiation and gene expression, independent of interleukin-5, and regardless of inclusion of cytokines to induce other lineages. In contrast, the putative repressor C/EBP-e27 isoform strongly inhibits eosinophil differentiation and gene expression, including GATA-1, promoting granulocyte (neutrophil)-macrophage differentiation. The C/EBP-ε14 repressor isoform strongly inhibits eosinophil development and gene expression, promoting erythroid differentiation, an effect enhanced by erythropoietin. Thus, C/EBP-ε isoforms can reprogram myeloid lineage commitment and differentiation consistent with their predicted activities based on activator and repressor domains and in vitro functional activities.
AB - CCAAT enhancer-binding protein-epsilon (C/EBP-ε) is required for the terminal differentiation of neutrophils and eosinophils. Human C/EBP-ε is expressed as 4 isoforms (32,30,27, and 14 kDa) through differential RNA splicing, and alternative promoters and translational start sites. The C/EBP-ε32/30 isoforms are transcriptional activators, whereas C/EBP-ε27 interacts with and represses GATA-1 transactivation of eosinophil promoters. C/EBP-ε14 contains only DNA-binding and -dimerization domains and may function as a dominant-negative regulator. To define functional activities for these C/EBP-ε isoforms in myelopoiesis, human CD34+ progenitors were transduced with internal ribosomal entry site-enhanced green fluorescent protein retroviral vectors encoding the 32/30, 27, and 14-kDa isoforms, purified by fluorescence-activated cell sorter, and analyzed in colony-forming assays and suspension cultures. Progenitors transduced with C/EBP-ε32/30 default exclusively to eosinophil differentiation and gene expression, independent of interleukin-5, and regardless of inclusion of cytokines to induce other lineages. In contrast, the putative repressor C/EBP-e27 isoform strongly inhibits eosinophil differentiation and gene expression, including GATA-1, promoting granulocyte (neutrophil)-macrophage differentiation. The C/EBP-ε14 repressor isoform strongly inhibits eosinophil development and gene expression, promoting erythroid differentiation, an effect enhanced by erythropoietin. Thus, C/EBP-ε isoforms can reprogram myeloid lineage commitment and differentiation consistent with their predicted activities based on activator and repressor domains and in vitro functional activities.
UR - http://www.scopus.com/inward/record.url?scp=58849093683&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58849093683&partnerID=8YFLogxK
U2 - 10.1182/blood-2008-02-139741
DO - 10.1182/blood-2008-02-139741
M3 - Article
C2 - 18832658
AN - SCOPUS:58849093683
SN - 0006-4971
VL - 113
SP - 317
EP - 327
JO - Blood
JF - Blood
IS - 2
ER -